Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001628280-25-010672
Filing Date
2025-03-05
Accepted
2025-03-05 18:32:06
Documents
1
Period of Report
2025-03-03

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1741217520.html 4  
1 FORM 4 wk-form4_1741217520.xml 4 12399
  Complete submission text file 0001628280-25-010672.txt   14199
Mailing Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105
Business Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105 626-696-4702
ARROWHEAD PHARMACEUTICALS, INC. (Issuer) CIK: 0000879407 (see all company filings)

EIN.: 460408024 | State of Incorp.: DE | Fiscal Year End: 0930
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address ARROWHEAD RESEARCH CORPORATION 201 SOUTH LAKE AVENUE, SUITE 703 PASADENA CA 91101
Business Address
Anzalone Christopher Richard (Reporting) CIK: 0001423029 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38042 | Film No.: 25712947